GT Biopharma Investor Relations Material

GT Biopharma Inc. is a biotechnology company focused on developing immuno-oncology therapies for cancer treatment. The company specializes in TriKE (Tri-specific Killer Engager) technology, which is designed to enhance the ability of natural killer (NK) cells to target and destroy cancer cells. GT Biopharma’s pipeline includes investigational treatments for hematologic malignancies and solid tumors. The company is headquartered in Brisbane, California, and its shares are listed on the NASDAQ.